Prognostic significance of germline ARID5B and LEPR polymorphisms in intrahepatic and perihilar cholangiocarcinoma after curative resection

Table 1 Patient characteristics, n (%)/median and interquartile range

Variables	iCCA (n = 112)	pCCA (n = 117)
Demographics
Gender, M/F (%)	49 (43.8)/63 (56.3)	78 (66.7)/39 (33.3)
Age (years)	65 (58-75)	69 (58-74)
ASA
I	3 (2.7)	6 (5.1)
II	45 (40.2)	47 (40.2)
III	59 (52.7)	58 (49.6)
IV	5 (4.5)	6 (5.1)
V	0	0
Bismuth type
I		7 (6.0)
II		13 (11.1)
IIIa		29 (24.8)
IIIb		33 (28.2)
IV		35 (29.9)
Cholangitis	4 (3.6)	30 (25.6)
Portal vein embolization	7 (6.3)	41 (35.0)
Preoperative chemotherapy	9 (8.0)	5 (4.3)
Clinical chemistry
AST (U/L)	34 (26-47)	47 (34-95)
ALT (U/L)	29 (20-49)	69 (36-144)
Albumin (g/dL)	4.4 (4.0-4.6)	3.9 (3.5-4.2)
AP (U/L)	118 (84-215)	254 (159-423)
CA19-9 (U/mL)	39.5 (13.9-236.3)	85.8 (31.2-287.7)
CRP (mg/L)	7.5 (2.8-19.4)	11.8 (5.4-34.7)
GGT (U/L)	113 (65-275)	472 (216-756)
Hemoglobin (g/dL)	13.1 (12.2-14.3)	12.4 (11.2-13.3)
INR	1.0 (0.9-1.1)	1.0 (0.9-1.1)
Platelet count (nL)	252 (202-306)	293 (229-388)
Prothrombin time (%)	100 (90-108)	96 (81-105)
Total bilirubin (mg/dL)	0.5 (0.3-0.7)	1.1 (0.5-2.8)
Operative data
Intraoperative PRBC	31 (72.3)	54 (46.2)
Intraoperative FFP	38 (33.9)	68 (58.1)
Operative time (minutes)	295 (230-359)	420 (356-485)
Operative procedure
Hemihepatectomy	44 (39.2)	29 (24.8)
Extended hemihepatectomy	17 (15.1)	54 (46.2)
Trisectionectomy	12 (10.8)	24 (20.6)
Hepatoduodenoectomy	0 (0)	5 (4.3)
ALPPS	10 (8.9)	1 (0.9)
Others	29 (25.8)	4 (3.4)
Time to surgery (days1)	45 (29-83)	38 (24-56)
Pathological examination
LVI	20 (17.9)	26 (22.2)
MVI	5 (4.5)	2 (1.7)
R0 resection	97 (86.6)	97 (82.9)
pT category
1	46 (41.1)	10 (8.6)
2	46 (41.1)	72 (61.5)
3	12 (10.7)	26 (22.2)
4	8 (7.1)	9 (7.7)
pN category
N0	69 (61.6)	67 (57.3)
N1	34 (30.4)	50 (42.7)
Tumor grading
G1	0	7 (6.0)
G2	73 (65.2)	83 (70.9)
G3	26 (23.2)	22 (18.8)
G4	3 (2.7)	1 (0.9)
Postoperative data
Intensive care (days)	1 (1-1)	1 (1-2)
Hospitalization (days)	12 (8-22)	17 (12-36)
Postoperative complications
No complications	43 (38.4)	19 (16.2)
Clavien-Dindo I	4 (3.6)	8 (6.8)
Clavien-Dindo II	24 (21.4)	33 (28.2)
Clavien-Dindo IIIa	25 (22.3)	25 (28.2)
Clavien-Dindo IIIb	10 (8.9)	19 (16.2)
Clavien-Dindo IVa	5 (4.5)	8 (6.8)
Clavien-Dindo IVb	1 (0.9)	5 (4.3)
Clavien-Dindo V	0	0
Oncologic data
Adjuvant chemotherapy	42 (37.5)	31 (26.5)
Recurrence	77 (68.8)	64 (54.7)
Median RFS, months (95%CI)	12 (7-17)	37 (23-51)
Median CSS, months (95%CI)	28 (21-35)	49 (24-74)
Median OS, months (95%CI)	25 (18-32)	33 (20-46)

¹Time to surgery refers to the time frame from diagnosis to surgery.

iCCA: Intrahepatic cholangiocarcinoma; pCCA: Perihilar cholangiocarcinoma; M: Male; F: Female; AP: Alkaline Phosphatase; ASA: American Society of Anesthesiology; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; CA19-9: Carbohydrate antigen 19-9; CRP: C-reactive protein; GGT: Gamma-glutamyl transpeptidase; INR: International normalized ratio; PRBC: Packed red blood cells; FFP: Fresh frozen plasma; ALPPS: Associating liver partition with portal vein ligation for staged hepatectomy; LVI: Lymph vascular invasion; MVI: Microvascular invasion; CSS: Cancer-specific survival; OS: Overall Survival; RFS: Recurrence free survival.